A Randomized, Double-blind, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Dose De-escalation of Orally Administered Filgotinib in Subjects With Ulcerative Colitis in Clinical Remission
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Filgotinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms CAPYBARA
- Sponsors Galapagos NV
- 04 Oct 2024 Study design 'open label' cancelled.
- 30 May 2024 This trial has been Completed in Poland, according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been Completed in Italy (End Date: 09 Oct 2023), according to European Clinical Trials Database record.